Project Grant R01EY037660
- Federal Grant Award Summary The Schepens Eye Research Institute, Inc. received a $295,500 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 15, 2025, through August 31, 2027. This research initiative focuses on developing a cytoprotective and pro-regenerative therapeutic countermeasure to mitigate ocular damage caused by mustard gas exposure. The project investigates the...
- Federal Project Grant Summary The University of Connecticut Health Center received a $1.47M Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 15, 2025 through August 31, 2028. This award funds research investigating corneal and Schwann cell mechanisms in vesicant injury caused by chemical threat agents such as sulfur mustard and nitrogen mustard. The research deliverables include...
- Federal Project Grant Award Summary The University of Texas Medical Branch at Galveston received a $2.88 million Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 15, 2025, with a completion date of August 31, 2028. This research initiative investigates the role of Sirtuin 6 (SIRT6), a histone deacetylase protein, in mitigating corneal and retinal injury caused by acrolein...
- Federal Grant Award Summary This Project Grant, awarded on April 23, 2026, by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), provides $1.40 million in funding to Michigan State University's Henry Ford Health + Michigan State University Health Sciences partnership through April 22, 2029. The award supports research investigating the mechanisms of lung toxicity resulting from skin exposure to vesicating agents,...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $810,171 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research investigating the therapeutic effects of peroxisome proliferator-activated receptor alpha (PPAR-α) agonists as a treatment intervention for combat-induced proliferative vitreoretinopathy, an...
- Federal Project Grant Award Summary The University of Virginia received a $1.46 million Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded on April 14, 2026, with a three-year performance period concluding April 13, 2029. The project, titled "Preserving Lung Integrity and Harnessing Inflammation to Treat Vesicant-Induced Lung Injury," focuses on developing therapeutic approaches to...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $770,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 15, 2025, for the development and advancement of biocompatible cryopreservation techniques for eyelid and periorbital tissues. The three-year project, with an ultimate completion date of September 14, 2028, will be conducted at the awardee's facility in...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a Project Grant totaling $900,600 to The Regents of the University of California, San Francisco, with an award date of September 1, 2025, and completion date of August 31, 2027, under the Vision Research program (CFDA 93.867). This award funds research directed at understanding corneal limbal stem cells (LSCs) during wound healing processes. The project addresses the significant clinical need for restorative treatments for...
- Federal Grant Award Summary New York University School of Medicine received a $546,439 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded April 15, 2026, with completion anticipated by March 31, 2030. The award funds research to develop corneal stromal keratocyte modeling from human cornea organoids (HCOs) as a potential therapy for corneal scarring and keratoconus-related blindness. The research leverages HCOs generated from induced...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Schepens Eye Research Institute, Inc. a Project Grant totaling $1,466,706 under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The award supports research and development services focused on "Topical Oxygen for Pan-Ocular Protection (TOPP) Against Severe Chemical Injury," an initiative designed to develop innovative medical...
Wake Forest University Health Sciences received a $1.36M Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective April 1, 2026 through March 31, 2029. The award supports research to identify single-cell determinants of corneal injury progression following sulfur mustard exposure. Using a translational rabbit model of sulfur mustard vapor exposure, the research team will employ single-cell RNA sequencing, immunohistochemistry, and in situ hybridization techniques to characterize cellular and molecular pathways involved in the transition from acute corneal lesion to mustard gas keratopathy (MGK). The ultimate objective is to identify therapeutic targets that could prevent or mitigate the onset of MGK, a debilitating ocular condition affecting up to 90% of high-dose sulfur mustard exposure casualties and characterized by corneal neovascularization, photophobia, dry eye, chronic pain, and progressive corneal decompensation. The research deliverables include comprehensive characterization of corneal cell populations present during injury progression and identification of pathological adaptive responses at the cellular level that could inform treatment development. Preliminary findings suggest that interventions blocking acute corneal edema demonstrate strong therapeutic effects, providing a foundational basis for the proposed investigation. This work addresses a significant gap in treatment options, as no specific therapies currently exist to prevent or reverse MGK in chemically injured eyes.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.4m | 4/2/26 |